were isolated from the peripheral blood mononuclear cells (PBMCs). The constructed CAR gene was inserted into a lentiviral plasmid containing the green fluorescent protein (GFP) tag and lentiviral particles were produced. These lentiviral particles were used to transduce activated T-cells by spinoculation. T-cells were activated using Dynabeadconjugated CD3/CD28 human T-cell activator and interleukin-2 (IL-2) before transduction. CD3+ T-cells were selected and GFP expression, which indicated transduction, was observed. Future studies will focus on in vitro and in vivo models to determine the efficiency of CAR-T cells in specifically targeting ERBB2-expressing cells.
INTRODUCTION
T-cells of the immune system can eradicate disease at extreme specificity by identifying the antigen expressed by the antigen presenting cells (Maher 2012) . T-cell receptors (TCRs) present on the T-cells engage antigens that are presented by the major histocompatibility complex (MHC) molecules (Maher 2012) . In most inflammatory conditions, an adaptive immune response is triggered following the presentation of peptides (non-self) by MHC molecules to immune cells. However, during tumor progression, the immune system often perceives tumor antigens as 'self' rather than foreign, hence becomes tolerant to tumors (Whiteside 2010) .
To overcome this challenge, researchers designed genetically-modified T-cells to specifically target the desired tumor-associated antigens (TAAs) (Jena et al. 2010) . The T-cells were equipped with a Chimeric Antigen Receptor (CAR). A CAR links an antigen specific singlechain antibody fragment (scFv) to intracellular signalling domains, CD28 and CD3-ζ chain of the T-cell receptor (TCR) (Porter et al. 2011) . The scFv segment of the CAR is able to directly target and bind to the TAA on the tumor cells, bypassing the MHC immune recognition (Maher 2012) . Thus, genetically-modified T-cells to express CAR retain its immunogenic functions against tumor cells.
Human epidermal growth factor receptor 2 (ERBB2) is an antigen of interest for CAR technology because ERBB2 overexpression in breast cancer (occurring in 15-25% of cases) (Iqbal & Iqbal 2014 ) is associated with increased tumor aggression, resistance to chemotherapeutics and ultimately poor patient prognosis (Eroles et al. 2012 ). ERBB2 overexpression is also observed in endometrial cancer (12% of cases) (Elsahwi & Santin 2011) , gastric and esophageal cancer (15-20% of cases) (Iqbal & Iqbal 2014) , in addition too varian (Teplinsky & Muggia 2015) , stomach (Iqbal & Iqbal 2014) , bladder (Iqbal & Iqbal 2014 ) and lung carcinomas (Iqbal & Iqbal 2014) (Figure 1 ). ERBB2 positive breast cancer patients are treated with anti-ERBB2 therapy in addition to surgery, chemotherapy and radiation (Carey 2011) . Treatment options for anti-ERBB2 therapies include the monoclonal antibodies trastuzumab and pertuzumab (Scott et al. 2012) . Hormone therapies such as tamoxifen (Indah et al. 2015) and aromatase inhibitors (Dieci et al. 2016 ) are also available.
Current clinical trials trend is moving towards immunotherapeutic strategies such as checkpoint inhibitors, oncolytic viruses and anti-ERBB2 intracellular singlechain antibodies (Marchini et al. 2016) . Novel avenues such as ERBB2-specific tyrosine kinase inhibitors (i.e. emodin) (Schroeder et al. 2014 ), ERBB2-targeting antisense oligonucleotides (Han et al. 2013 ) and rationally designed anti-ERBB2 peptide mimetics (Govindarajan et al. 2012) are also undergoing different stages of clinical trials (Figure 1 ). The limitations of chemotherapy and radiation include the fact that they not only affect cancerous cells, but also target all actively dividing healthy cells. This can lead to prominent side effects including loss of appetite, hair loss, nausea and vomiting, extreme fatigue, mouth soreness, bleeding and low immunity against infections (Carey 2011) (Figure 1) . Thus, ERBB2 is a suitable TAA for use in CAR technology.
The genetic-modification of T-cells to express CAR involves the delivery of CAR gene via viral transduction into autologous human T-cells. A huge problem concerning T-cell manipulation involves the foremost step of isolating a pure population of T-cells from patient's blood for use in immunotherapy (Stemberger et al. 2014) . Previous studies adopting the CAR method have largely manipulated the CD8+ T-cells sub-population within the CD3+ T-cells (Jensen et al. 2010; Zhong et al. 2009 ). However, achieving clinically significant numbers via ex vivo expansion of this modified population of CD8+ T-cells are difficult (Maher 2012) . Furthermore, primary human T-cells are resistant to transduction by virus, as naïve T-cells are non-proliferating or quiescent cells in vitro. CAR gene integration into the genome of the transduced T-cells will also require prior activation through the TCR and cytokines (Zack et al. 2013) . In order to overcome the multitude of challenges involved in the CAR gene delivery into T-cells, we optimized a robust protocol for the fast and efficient transduction of CAR into human T-cells.
In the current study, we aimed to optimize a transduction protocol to efficiently deliver CAR gene into human CD3+ T-cells. The CAR gene consists of an anti-ERBB2 scFv extracellular domain followed by the CD8 transmembrane domain and two co-stimulatory domains, namely, CD28 and CD3-ζ (ERBB2 scFv-CD8a-CD28-CD3-ζ). This would be able to specifically target ERBB2 antigens on tumor cells with increased efficiency and reduced side effects.
MATERIAL AND METHODS HUMAN T-CELLS CULTURE AND EXPANSION
Ten milliliters of collected blood samples from healthy donors (National Medical Research Register, Malaysia; ethical approval number: NMRR-14-587-20201) were processed to isolate peripheral blood mononuclear cells (PBMCs) by density gradient separation using Ficoll-Paque PLUS (1.077 g/mL, Amersham Biosciences, Sweden). Isolated human PBMCs were cultured in advanced RPMI 1640 media (Gibco/Invitrogen, Massachusetts, USA), supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin (Pen/Strep), and 0.1% gentamycin at 37°C and 5% CO 2 concentration. CD3+ cells were then isolated from PBMCs using an EasySep™ Human T Cell Enrichment Kit (Stem Cell Technologies,Vancouver, Canada) following manufacturer's protocol. The isolated CD3+ T-cells in complete culture media were mixed with Dynabead-conjugated CD3/CD28 human T-cell activator (1:10 ratio) (Gibco/Invitrogen, Massachusetts, USA) and 50 U/mL of interleukin-2 (IL-2) (PeproTech, Rocky Hill, USA) for activation.
FLOW CYTOMETRIC ANALYSIS
To detect surface antigens, aliquots of cultured T-cells were washed twice with phosphate-buffered saline (PBS) (Gibco/Invitrogen; Massachusetts, USA), pH 7.2 after centrifugation at 1000 × g for 5 min. The cells were incubated with fluorescein isothiocyanate (FITC), allophycocyanin (APC), phycoerythrin (PE) or phycoerythrin Cyanine7 (PE-Cy7) conjugated monoclonal antibodies on ice for 45 min. The antibodies used were CD3, CD4, CD8, CD25 and CD69, all purchased from Affymetrix eBioscience, Inc. (San Diego, USA). After incubation, the cells were washed twice by centrifugation at 300 × g for 5 min and subjected to flow cytometric analysis. In parallel, unstained and fluorochrome matched, non-specific isotype labeled cells were used as controls. The stained samples were assessed using BD FACS Canto II (Becton Dickinson (BD) BioSciences; New Jersey, USA). Gating at FACS acquisition was applied to exclude any dead cells and cell debris. Ten thousand events were acquired and the data from stained cells were acquired using FACSDiva 6.1.3 software (Becton Dickinson (BD) BioSciences; New Jersey, USA).
PLASMID CONSTRUCTION pReceiver-Lv 183 lentiviral expression plasmid (GeneCopoeia Rockville, USA) containing a green fluorescent protein (GFP) selection marker located downstream of the inserted CAR target gene was used. The CAR gene was synthesized according to the WO2012031744 (NCBI accession number: JB399738) patent number and consisted of 1515 bp.
LENTIVIRAL PARTICLE PRODUCTION
The Lenti-Pac™ HIV Expression Packaging Kit from GeneCopoeia (Rockville, MD, USA) was used in combination with the lentiviral expression plasmid (pReceiver-Lv 183) containing the CAR gene to produce complete viral particles. The lentiviral vectors were produced using the packaging cell line, 293FT. A total of 2.5 μg, 4.0 μg or 5.5 μg of lentiviral expression plasmid and 5.0 μL (0.5 μg/μL) of Lenti-Pac HIV mix were diluted in a sterile tube containing 200 μL of Opti-MEM® I (Gibco/ Invitrogen; Massachusetts, USA). In a separate tube, 15 μL of EndoFectin Lenti reagent was diluted into 200 μL of Opti-MEM I. The diluted EndoFectin Lenti reagent was then mixed with the DNA solution before adding it to the 293FT cells. Cells were then incubated in a CO 2 incubator at 37°C. After 12 h, the overnight culture medium was replaced with fresh DMEM with 5% FBS and 1% Pen/ Strep. The pseudovirus-containing culture medium was collected at 48 h post-transfection. The supernatant was then concentrated using amicon viral concentration ultrafiltration 100 kDa tubes (Merck Milipore; Darmstadt, Germany) with centrifugation at 1200 × g for 15 min at 4°C. The freshly collected concentrated virus supernatant was used for transduction of T-cells.
TRANSDUCTION OF CAR GENE INTO T-CELLS VIA LENTIVIRUS EXPRESSION SYSTEM
A total of 2 × 10 5 T-cells were plated on a 24-well plate 24 h before viral infection. Viral media were prepared with 0.5 mL of virus suspension diluted in complete medium with polybrene (8 μg/mL). The target CD3+ T-cells were infected by adding the viral media. For the control well, 0.5 mL of complete medium with polybrene only was added. The cells were spinoculated at 800 × g for 1.5 h at 32°C. The plates were incubated overnight in a CO 2 incubator. The culture media were replaced with fresh complete media (without polybrene) 12 h after transduction. The infected target T-cells were analyzed for transgene expression using the internal GFP control via fluorescence microscopy.
RESULTS EFFICIENT ISOLATION OF CD3+ T-CELLS FROM HUMAN PBMCS USING MAGNETIC SELECTION
Fresh blood was collected and the PBMC layer was isolated by density gradient centrifugation. To further enhance the lymphocyte concentration for downstream experimental work, the PBMC layer was subjected to magnetic separation of CD3+ T-cells using the EasySep™ Human T Cell Enrichment Kit. Our results showed an increase in CD3+ T-cells after magnetic selection (Figure 2 ). The selection process was extremely efficient in enriching for a homogenous T-cells population by depleting all other PBMCs and as a result, the T-cells population was increased from 78.2% to 99.4%. The isolated CD3+ cells were activated for transduction and expansion.
SUCCESSFUL ACTIVATION OF ISOLATED CD3+ T-CELLS
Morphological observation of CD3+ T-cells showed that non-activated T-cells appeared as single spherical suspension in culture. Meanwhile, activated T-cells supplemented with Dynabead-conjugated CD3/CD28 human T-cell activator and IL-2 appeared as clumped cells (Figure 3(A) ). Figure 3( (Figure 3(B) ). This indicates that the activation protocol employed was successful in inducing activation of T-cell, priming them for efficient transduction. This result was consistent between variations in variables including the donor and passage of the cells (data not shown). All flow cytometry dot plots were compared to specific isotype controls.
PRODUCTION OF CAR LENTIVIRAL PARTICLES AND HUMAN T-CELL TRANSDUCTION
We transfected 293FT packaging cells using three different concentrations of the CAR transfer plasmid (2.5, 4.0 and 5.5 μg) to produce lentivirus particles (Figure 4) . From Figure  4 , we observed that GFP expression using 5.5 μg of the CAR transfer plasmid was visibly higher than that of 2.5 μg or 4.0 μg of the CAR transfer plasmid in the 293FT cells 48 h post-transfection. Following that, the supernatants were 
DISCUSSION
The CD3 surface marker is expressed on all T-cells and is associated with TCR (Ahmadi et al. 2011 ). An approximate of 70-80% of human peripheral blood lymphocytes are composed of CD3+ T-cells whereas only 30% of the CD3+ T-cells is comprised of CD8+ T-cells (Rivkina et al. 2015; Sinon et al. 2013) . The pre-selection of CD3+ T-cells to ensure a homogeneous T-cell population is vital, as the homogenous equilibrium of cells in patient's blood can be interrupted by malignant proliferative changes generated by cancer (Rivkina et al. 2015) . Deriving blood from cancer patients for an autologous immunotherapy without extensive pre-selection will affect the efficiency and might result in unwanted complications during in vivo clinical applications. Thus, for this purpose, we have proposed that selecting T-cells based on CD3+ T-cell marker is not only sufficient but superior to selecting T-cells at the subpopulation of CD8+. Selecting patient sample at CD3+ T-cells would overcome the challenge of limited cell availability and proliferative capability conferred by CD8+ T-cells. Furthermore, cancer immunotherapy is dependent on the ability of CD3+ T-cells to home and eradicate tumor cells in vivo (Bollard et al. 2012) . Transduction of primary human T-cells poses a problem as T-cells are non-dividing quiescent cells in vitro (Zack et al. 2013) . Multiple strategies can be adopted to increase the viral titer and transduction efficiency, including optimization of the transfer plasmid and viral particle concentrations and modifications to the culture conditions such as spinoculation (Cribbs et al. 2013) . Lentiviral vectors are favored for advantageous traits such as the ability to transfer genes into both dividing and non-dividing T-cells; in contrast, retroviral methods typically can only be used to transfer genes into dividing cells (Cribbs et al. 2013) . As non-activated T-cells are primarily non-dividing cells, lentivirus allows for more stable and long-term transduction of cells with a lower tendency towards gene silencing, when compared to retroviruses (Shaw & Cornetta 2014 ).
In the current study, isolated PBMCs were subjected to magnetic separation to generate a highly homogenous CD3+ T-cells population (Figure 2 ). The isolated CD3+ T-cells were activated and transduced with lentiviral particles encoding the CAR gene. Figure 5 shows a schematic representation of the complete experimental protocols employed in this study, including human T-cells isolation, activation, culture, transduction and ultimately determination of transduction efficiency via fluorescence microscopy.
Here, we demonstrated that activation of the isolated CD3+ T-cells with Dynabead-conjugated CD3/CD28 human T-cell activator and interleukin-2 (IL-2) before transduction and optimization of the CAR transfer plasmid at 5.5 μg of concentration in a fast and efficient method via spinoculation could result in increased transduction efficiency. Higher transduction efficiency is vital for downstream applications to evaluate CAR-T cell targeting (Chmielewski et al. 2013) . Upon activation by a target cell via the binding of the anti-ERBB2 scFv segment on the CAR-T cells to the ERBB2 antigen on the tumor cells, the CAR-T cells trigger immune activity. CAR-T cells execute the exocytosis of secretory granules containing perforin and the proapoptotic serine protease, granzyme B (De Saint Basile et al. 2010), which induces apoptosis by cleaving critical substrates in tumor cells (Chmielewski et al. 2013) . Figure  6 is a schematic representation of the apoptotic mechanism exerted by CAR-T-cells upon binding to ERBB2 antigens on a tumor cell. Following ligation, CAR-T cells release perforin and granzyme B to increase the secretion of proinflammatory cytokines such as interferon-gamma (IFN-γ) and interleukin-2 (IL-2).
CONCLUSION
The current study was able to optimize an efficient method for the transduction of the CAR gene specific for ERBB2 antigen into human CD3+ T-cells via spinoculation. We overcame the challenges of transducing primary T-cells by selecting at CD3+ T-cell marker, activating the T-cells prior to transduction and increasing the CAR lentiviral transfer plasmid concentration. Future studies should determine the efficiency of specific targeting and killing mediated by the transduced CAR-T-cells upon co-culture with the ERBB2-overexpressing cancer cell line.
